<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">epilepsia</journal-id><journal-title-group><journal-title xml:lang="en">Epilepsy and paroxysmal conditions</journal-title><trans-title-group xml:lang="ru"><trans-title>Эпилепсия и пароксизмальные состояния</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2077-8333</issn><issn pub-type="epub">2311-4088</issn><publisher><publisher-name>IRBIS LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17749/2077-8333/epi.par.con.2021.049</article-id><article-id custom-type="elpub" pub-id-type="custom">epilepsia-657</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>SCIENTIFIC SURVEYS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НАУЧНЫЕ ОБЗОРЫ</subject></subj-group></article-categories><title-group><article-title>Acute symptomatic seizures during haematopoietic stem cell transplantation</article-title><trans-title-group xml:lang="ru"><trans-title>Остро возникшие симптоматические эпилептические приступы при проведении трансплантации гемопоэтических стволовых клеток</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1955-1032</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Скиба</surname><given-names>Я. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Skiba</surname><given-names>Ya. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Скиба Ярослав Богданович, к.м.н., врач-невролог Научно-исследовательского института детской онкологии, гематологии и трасплантологии им. Р.М. Горбачевой</p><p>Scopus Author ID: 57211950985</p><p>WoS ResearcherID: ABC-9723-2020</p><p>РИНЦ SPIN-код: 1273-0742</p><p>ул. Льва Толстого, д. 6-8, Санкт-Петербург 197022</p></bio><bio xml:lang="en"><p>Yaroslav B. Skiba, MD, PhD, Neurologist, Gorbacheva Research Institute of Pediatric Oncology, Hematology and TrasplantologyScopus Author ID: 57211950985</p><p>WoS ResearcherID: ABC-9723-2020</p><p>RSCI SPIN-code: 1273-0742</p><p>6-8 Lev Tolstoi Str., Saint Petersburg 197022</p></bio><email xlink:type="simple">yaver-99@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8699-2482</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полушин</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Polushin</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Полушин Алексей Юрьевич, к.м.н., ассистент кафедры неврологии, врач-невролог Научно-исследовательского института детской онкологии, гематологии и трасплантологии им. Р.М. Горбачевой</p><p>Scopus Author ID: 57195962540</p><p>РИНЦ SPIN-код: 8123-7779</p><p>ул. Льва Толстого, д. 6-8, Санкт-Петербург 197022</p></bio><bio xml:lang="en"><p>Aleksey Yu. Polushin, MD, PhD, Assistant Professor, Chair of Neurology, Neurologist, Gorbacheva Research Institute of PediatricOncology, Hematology and Trasplantology</p><p>Scopus Author ID: 57195962540</p><p>RSCI SPIN-code: 8123-7779</p><p>6-8 Lev Tolstoi Str., Saint Petersburg 197022</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1545-8877</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Прокудин</surname><given-names>М. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Prokudin</surname><given-names>M. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Прокудин Михаил Юрьевич, к.м.н., преподаватель кафедры нервных болезней им. М.И. Аствацатурова</p><p>РИНЦ SPIN-код: 4021-4432</p><p>ул. Льва Толстого, д. 6-8, Санкт-Петербург 197022</p></bio><bio xml:lang="en"><p>Mikhail Yu. Prokudin, MD, PhD, Astvatsaturov Chair of Nervous Diseases</p><p>RSCI SPIN-code: 4021-4432</p><p>6-8 Lev Tolstoi Str., Saint Petersburg 197022</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0215-4623</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Владовская</surname><given-names>М. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Vladovskaya</surname><given-names>M. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Владовская Мария Давидовна, к.м.н., заведующая отделением госпитальных регистров Научно-исследовательского института детской онкологии, гематологии и трасплантологии им. Р.М. Горбачевой </p><p>Scopus Author ID: 57194451100</p><p>РИНЦ SPIN-код: 9257-2440</p><p>ул. Льва Толстого, д. 6-8, Санкт-Петербург 197022</p></bio><bio xml:lang="en"><p>Mariya D. Vladovskaya, MD, PhD, Head of the Department of Hospital Registers, Gorbacheva Research Institute of PediatricOncology, Hematology and Trasplantology</p><p>Scopus Author ID: 57194451100</p><p>RSCI SPIN-code: 9257-2440</p><p>6-8 Lev Tolstoi Str., Saint Petersburg 197022</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9589-4136</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кулагин</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Kulagin</surname><given-names>A. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кулагин Александр Дмитриевич – д.м.н., и.о. директора Научно-исследовательского института детской онкологии, гематологии и трасплантологии им. Р.М. Горбачевой</p><p>Scopus Author ID: 7003340367</p><p>WoS ResearcherID: L-9795-2014</p><p>РИНЦ SPIN-код: 2667-4966</p><p>ул. Льва Толстого, д. 6-8, Санкт-Петербург 197022</p></bio><bio xml:lang="en"><p>Aleksandr D. Kulagin, Dr. Med. Sc., Acting Director, Gorbacheva Research Institute of Pediatric Oncology, Hematology andTrasplantology</p><p>Scopus Author ID: 7003340367</p><p>WoS ResearcherID: L-9795-2014</p><p>RSCI SPIN-code: 2667-4966</p><p>6-8 Lev Tolstoi Str., Saint Petersburg 197022</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pavlov First Saint Petersburg State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>23</day><month>04</month><year>2021</year></pub-date><volume>13</volume><issue>1</issue><fpage>65</fpage><lpage>82</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Skiba Y.B., Polushin A.Y., Prokudin M.Y., Vladovskaya M.D., Kulagin A.D., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Скиба Я.Б., Полушин А.Ю., Прокудин М.Ю., Владовская М.Д., Кулагин А.Д.</copyright-holder><copyright-holder xml:lang="en">Skiba Y.B., Polushin A.Y., Prokudin M.Y., Vladovskaya M.D., Kulagin A.D.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.epilepsia.su/jour/article/view/657">https://www.epilepsia.su/jour/article/view/657</self-uri><abstract><p>Acute symptomatic epileptic seizures are one of the complications of hematopoietic stem cell transplantation. The etiological factors leading to the development of this complication differ from those in the general population, while the significance of each of them is different depending on the time after transplantation. We analyze the literature data on the role of drugs, metabolic disorders and infectious complications, as well as the structural pathology of the brain substance in the development of acute symptomatic seizures in patients with oncohematological pathology. We also consider the clinical features of symptomatic epileptic seizures and the possible prognostic significance of their development in patients who underwent hematopoietic stem cell transplantation.</p></abstract><trans-abstract xml:lang="ru"><p>Одним из осложнений трансплантации гемопоэтических стволовых клеток у пациентов онкогематологического  профиля являются остро возникшие симптоматические  эпилептические приступы. Этиологические факторы, приводящие к развитию данного осложнения, отличаются от  таковых в общей популяции, при этом значимость каждого  из них различна в зависимости от сроков после  трансплантации. В статье проанализированы данные  литературы, посвященной роли лекарственных препаратов,  метаболических нарушений и инфекционных осложнений, а  также структурной патологии вещества головного мозга в  развитии симптоматических эпилептических приступов у  больных онкогематологического профиля. Рассмотрены их  клинические особенности и возможное прогностическое  значение их развития у пациентов, перенесших  трансплантацию гемопоэтических стволовых клеток.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>Эпилептический приступ</kwd><kwd>лейкоз</kwd><kwd>трансплантация</kwd><kwd>гемопоэтические стволовые клетки</kwd><kwd>бусульфан</kwd><kwd>онкологические заболевания</kwd><kwd>аллогенная трансплантация</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Epileptic seizure</kwd><kwd>leukemia</kwd><kwd>transplantation</kwd><kwd>hematopoietic stem cells</kwd><kwd>busulfan</kwd><kwd>cancer</kwd><kwd>allogeneic transplantation.</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Афанасьев Б.В., Зубаровская Л.С., Моисеев И.С. Аллогенная трансплантация гемопоэтических стволовых клеток у детей: настоящее, проблемы, перспективы. Российский журнал детской гематологии и онкологии. 2015; 2 (2): 28–42. https://doi.org/10.17650/2311-1267-2015-2-2-28-42.</mixed-citation><mixed-citation xml:lang="en">Афанасьев Б.В., Зубаровская Л.С., Моисеев И.С. Аллогенная трансплантация гемопоэтических стволовых клеток у детей: настоящее, проблемы, перспективы. Российский журнал детской гематологии и онкологии. 2015; 2 (2): 28–42. https://doi.org/10.17650/2311-1267-2015-2-2-28-42.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Afanasyeva K.S., Barabanshchikova M.V., Bondarenko S.N., et al. Indications for hematopoietic stem cell transplantation. Cellular Therapy and Transplantation. 2019; 8 (4): 101–45. https://doi.org/10.18620/ctt-1866-8836-2019-8-4-101-145.</mixed-citation><mixed-citation xml:lang="en">Afanasyeva K.S., Barabanshchikova M.V., Bondarenko S.N., et al. Indications for hematopoietic stem cell transplantation. Cellular Therapy and Transplantation. 2019; 8 (4): 101–45. https://doi.org/10.18620/ctt-1866-8836-2019-8-4-101-145.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Паровичникова Е.Н., Савченко В.Г. Российские многоцентровые исследования по лечению острых лейкозов. Терапевтический архив. 2019; 91 (7): 4–13. https://doi.org/10.26442/00403660.2019.07.000325.</mixed-citation><mixed-citation xml:lang="en">Паровичникова Е.Н., Савченко В.Г. Российские многоцентровые исследования по лечению острых лейкозов. Терапевтический архив. 2019; 91 (7): 4–13. https://doi.org/10.26442/00403660.2019.07.000325.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bondarenko S.N., Moiseev I.S., Slesarchuk O.A., et al. Allogeneic hematopoietic stem cell transplantation in children and adults with acute lymphoblastic leukemia. Cellular Therapy and Transplantation. 2016; 5 (2): 12–20. https://doi.org/10.18620/1866-8836-2016-5-2-12-20.</mixed-citation><mixed-citation xml:lang="en">Bondarenko S.N., Moiseev I.S., Slesarchuk O.A., et al. Allogeneic hematopoietic stem cell transplantation in children and adults with acute lymphoblastic leukemia. Cellular Therapy and Transplantation. 2016; 5 (2): 12–20. https://doi.org/10.18620/1866-8836-2016-5-2-12-20.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Паина О.В., Рахманова Ж.З., Кожокарь П.В. и др. Результаты аллогенной трансплантации гемопоэтических стволовых клеток от совместимого неродственного и родственного гаплоидентичного донора у детей с младенческим лейкозом высокой группы риска в первой и второй ремиссии. Вопросы гематологии/ онкологии и иммунопатологии в педиатрии. 2020; 19 (2): 30–7. https://doi.org/10.24287/1726-1708-2020-19-2-30-37.</mixed-citation><mixed-citation xml:lang="en">Паина О.В., Рахманова Ж.З., Кожокарь П.В. и др. Результаты аллогенной трансплантации гемопоэтических стволовых клеток от совместимого неродственного и родственного гаплоидентичного донора у детей с младенческим лейкозом высокой группы риска в первой и второй ремиссии. Вопросы гематологии/ онкологии и иммунопатологии в педиатрии. 2020; 19 (2): 30–7. https://doi.org/10.24287/1726-1708-2020-19-2-30-37.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kang J.M., Kim Y.J., Kim J.Y., et al. Neurologic complications after allogeneic hematopoietic stem cell transplantation in children: analysis of prognostic factors. Biol Blood Marrow Transplant. 2015; 21 (6): 1091–8. https://doi.org/10.1016/j.bbmt.2015.02.007.</mixed-citation><mixed-citation xml:lang="en">Kang J.M., Kim Y.J., Kim J.Y., et al. Neurologic complications after allogeneic hematopoietic stem cell transplantation in children: analysis of prognostic factors. Biol Blood Marrow Transplant. 2015; 21 (6): 1091–8. https://doi.org/10.1016/j.bbmt.2015.02.007.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang X.H., Xu L.P., Liu D.H., et al. Epileptic seizures in patients following allogeneic hematopoietic stem cell transplantation: a retrospective analysis of incidence, risk factors, and survival rates. Clin Transplant. 2013; 27 (1): 80–9. https://doi.org/10.1111/ctr.12000.</mixed-citation><mixed-citation xml:lang="en">Zhang X.H., Xu L.P., Liu D.H., et al. Epileptic seizures in patients following allogeneic hematopoietic stem cell transplantation: a retrospective analysis of incidence, risk factors, and survival rates. Clin Transplant. 2013; 27 (1): 80–9. https://doi.org/10.1111/ctr.12000.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Полушин А.Ю., Владовская М.Д., Моисеев И.С. и др. Проблема неврологических осложнений после неродственной трансплантации гемопоэтических стволовых клеток и таргетной терапии при злокачественных гематологических заболеваниях. Сборник материалов научной конференции XXI «Давиденковские чтения». СПб.: Человек и его здоровье; 2019: 256–8.</mixed-citation><mixed-citation xml:lang="en">Полушин А.Ю., Владовская М.Д., Моисеев И.С. и др. Проблема неврологических осложнений после неродственной трансплантации гемопоэтических стволовых клеток и таргетной терапии при злокачественных гематологических заболеваниях. Сборник материалов научной конференции XXI «Давиденковские чтения». СПб.: Человек и его здоровье; 2019: 256–8.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Cordelli D.M., Masetti R., Zama D., et al. Etiology, characteristics and outcome of seizures after pediatric hematopoietic stem cell transplantation. Seizure. 2014; 23 (2): 140–5. https://doi.org/10.1016/j.seizure.2013.11.003.</mixed-citation><mixed-citation xml:lang="en">Cordelli D.M., Masetti R., Zama D., et al. Etiology, characteristics and outcome of seizures after pediatric hematopoietic stem cell transplantation. Seizure. 2014; 23 (2): 140–5. https://doi.org/10.1016/j.seizure.2013.11.003.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lipatova L.V., Rudakova I.G., Sivakova N.A., Kapustina T.V. Acute symptomatic epileptic seizures and status epilepticus. Zh Nevrol Psikhiatr Im S S Korsakova. 2015; 115 (4): 24–9 (in Russ.) https://doi.org/10.17116/jnevro20151154124-29.</mixed-citation><mixed-citation xml:lang="en">Lipatova L.V., Rudakova I.G., Sivakova N.A., Kapustina T.V. Acute symptomatic epileptic seizures and status epilepticus. Zh Nevrol Psikhiatr Im S S Korsakova. 2015; 115 (4): 24–9 (in Russ.) https://doi.org/10.17116/jnevro20151154124-29.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Annegers J.F., Hauser W.A., Lee J.R, Rocca W.A. Incidence of acute symptomatic seizures in Rochester, Minnesota, 1935–1984. Epilepsia. 1995; 36 (4): 327–33. https://doi.org/10.1111/j.1528-1157.1995.tb01005.x.</mixed-citation><mixed-citation xml:lang="en">Annegers J.F., Hauser W.A., Lee J.R, Rocca W.A. Incidence of acute symptomatic seizures in Rochester, Minnesota, 1935–1984. Epilepsia. 1995; 36 (4): 327–33. https://doi.org/10.1111/j.1528-1157.1995.tb01005.x.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Costello D.J., Cole A.J. Treatment of acute seizures and status epilepticus. J Intensive Care Med. 2007; 22 (6): 319–47. https://doi.org/10.1177/0885066607307506.</mixed-citation><mixed-citation xml:lang="en">Costello D.J., Cole A.J. Treatment of acute seizures and status epilepticus. J Intensive Care Med. 2007; 22 (6): 319–47. https://doi.org/10.1177/0885066607307506.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Khan R.B., Morris E.B., Pui C.H., et al. Long-term outcome and risk factors for uncontrolled seizures after a first seizure in children with hematological malignancies. J Child Neurol. 2014; 29 (6): 774–81. https://doi.org/10.1177/0883073813488675.</mixed-citation><mixed-citation xml:lang="en">Khan R.B., Morris E.B., Pui C.H., et al. Long-term outcome and risk factors for uncontrolled seizures after a first seizure in children with hematological malignancies. J Child Neurol. 2014; 29 (6): 774–81. https://doi.org/10.1177/0883073813488675.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Caselli D., Ziino O., Bartoli A., et al. Continuous intravenous infusion of lorazepam as seizure prophylaxis in children treated with high-dose busulfan. Bone Marrow Transplant. 2008; 42 (2): 135–6. https://doi.org/10.1038/bmt.2008.91.</mixed-citation><mixed-citation xml:lang="en">Caselli D., Ziino O., Bartoli A., et al. Continuous intravenous infusion of lorazepam as seizure prophylaxis in children treated with high-dose busulfan. Bone Marrow Transplant. 2008; 42 (2): 135–6. https://doi.org/10.1038/bmt.2008.91.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Tsujimoto S.I., Shirai R., Utano T., et al. Comparison of clonazepam and levetiracetam in children for prevention of busulfan-induced seizure in hematopoietic stem cell transplantation. Int J Hematol. 2020; 111 (3): 463–6. https://doi.org/10.1007/s12185-019-02795-8.</mixed-citation><mixed-citation xml:lang="en">Tsujimoto S.I., Shirai R., Utano T., et al. Comparison of clonazepam and levetiracetam in children for prevention of busulfan-induced seizure in hematopoietic stem cell transplantation. Int J Hematol. 2020; 111 (3): 463–6. https://doi.org/10.1007/s12185-019-02795-8.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Della Puppa A., Denaro L., Rossetto M., et al. Postoperative seizure in high grade glioma patients treated with BCNU wafers. A monoinstitutional experience. J Neurooncol. 2011; 105 (2): 275–80. https://doi.org/10.1007/s11060-011-0577-6.</mixed-citation><mixed-citation xml:lang="en">Della Puppa A., Denaro L., Rossetto M., et al. Postoperative seizure in high grade glioma patients treated with BCNU wafers. A monoinstitutional experience. J Neurooncol. 2011; 105 (2): 275–80. https://doi.org/10.1007/s11060-011-0577-6.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Biran N., Rowley S.D., Vesole D.H., et al. A phase i/ii study of escalating doses of bortezomib in conjunction with high-dose melphalan as a conditioning regimen for salvage autologous peripheral blood stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant. 2016; 22 (12): 2165–71. https://doi.org/10.1016/j.bbmt.2016.08.017.</mixed-citation><mixed-citation xml:lang="en">Biran N., Rowley S.D., Vesole D.H., et al. A phase i/ii study of escalating doses of bortezomib in conjunction with high-dose melphalan as a conditioning regimen for salvage autologous peripheral blood stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant. 2016; 22 (12): 2165–71. https://doi.org/10.1016/j.bbmt.2016.08.017.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ryan S.A., Maceneaney P., O'Reilly S.P., et al. Reversible posterior leukoencephalopathy induced by carboplatin and etoposide. Med Oncol. 2012; 29 (2): 1287–91. https://doi.org/10.1007/s12032-011-9898-8.</mixed-citation><mixed-citation xml:lang="en">Ryan S.A., Maceneaney P., O'Reilly S.P., et al. Reversible posterior leukoencephalopathy induced by carboplatin and etoposide. Med Oncol. 2012; 29 (2): 1287–91. https://doi.org/10.1007/s12032-011-9898-8.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kushner B.H., Cheung N.K., Kramer K., et al. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transplant. 2001; 28 (6): 551–6. https://doi.org/10.1038/sj.bmt.1703213.</mixed-citation><mixed-citation xml:lang="en">Kushner B.H., Cheung N.K., Kramer K., et al. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transplant. 2001; 28 (6): 551–6. https://doi.org/10.1038/sj.bmt.1703213.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Beitinjaneh A., McKinney A.M., Cao Q., Weisdorf D.J. Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011; 17 (3): 300–8. https://doi.org/10.1016/j.bbmt.2010.04.003.</mixed-citation><mixed-citation xml:lang="en">Beitinjaneh A., McKinney A.M., Cao Q., Weisdorf D.J. Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011; 17 (3): 300–8. https://doi.org/10.1016/j.bbmt.2010.04.003.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Meldgaard Knudsen L., Jensen L., Gaarsdal E., et al. A comparative study of sequential priming and mobilisation of progenitor cells with rhG-CSF alone and high-dose cyclophosphamide plus rhG-CSF. Bone Marrow Transplant. 2000; 26 (7): 717–22. https://doi.org/10.1038/sj.bmt.1702609.</mixed-citation><mixed-citation xml:lang="en">Meldgaard Knudsen L., Jensen L., Gaarsdal E., et al. A comparative study of sequential priming and mobilisation of progenitor cells with rhG-CSF alone and high-dose cyclophosphamide plus rhG-CSF. Bone Marrow Transplant. 2000; 26 (7): 717–22. https://doi.org/10.1038/sj.bmt.1702609.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Hwang S.B., Lee H.Y., Kim H.Y., et al. Life-threatening acute hyponatremia with generalized seizure induced by low-dose cyclophosphamide in a patient with breast cancer. J Breast Cancer. 2011; 14 (4): 345–8. https://doi.org/10.4048/jbc.2011.14.4.345.</mixed-citation><mixed-citation xml:lang="en">Hwang S.B., Lee H.Y., Kim H.Y., et al. Life-threatening acute hyponatremia with generalized seizure induced by low-dose cyclophosphamide in a patient with breast cancer. J Breast Cancer. 2011; 14 (4): 345–8. https://doi.org/10.4048/jbc.2011.14.4.345.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Kawakami K., Ito R., Kageyama Y., et al. Superior sagittal sinus thrombosis after intrathecal chemotherapy and intravenous high-dose cytarabine in an acute myeloid leukemia case with t(8;21)(q22;q22). Rinsho Ketsueki. 2016; 57 (4): 477–82 (in Japanese). https://doi.org/10.11406/rinketsu.57.477.</mixed-citation><mixed-citation xml:lang="en">Kawakami K., Ito R., Kageyama Y., et al. Superior sagittal sinus thrombosis after intrathecal chemotherapy and intravenous high-dose cytarabine in an acute myeloid leukemia case with t(8;21)(q22;q22). Rinsho Ketsueki. 2016; 57 (4): 477–82 (in Japanese). https://doi.org/10.11406/rinketsu.57.477.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Bauwens D., Hantson P., Laterre P.F., et al. Recurrent seizure and sustained encephalopathy associated with dimethylsulfoxidepreserved stem cell infusion. Leukemia&amp;Lymphoma. 2005; 46 (11): 1671–4. https://doi.org/10.1080/10428190500235611.</mixed-citation><mixed-citation xml:lang="en">Bauwens D., Hantson P., Laterre P.F., et al. Recurrent seizure and sustained encephalopathy associated with dimethylsulfoxidepreserved stem cell infusion. Leukemia&amp;Lymphoma. 2005; 46 (11): 1671–4. https://doi.org/10.1080/10428190500235611.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Maral S., Albayrak M., Pala C., et al. Dimethyl sulfoxide-induced tonic-clonic seizure and cardiac arrest during infusion of autologous peripheral blood stem cells. Cell Tissue Bank. 2018; 19 (4): 831–2. https://doi.org/10.1007/s10561-018-9718-x.</mixed-citation><mixed-citation xml:lang="en">Maral S., Albayrak M., Pala C., et al. Dimethyl sulfoxide-induced tonic-clonic seizure and cardiac arrest during infusion of autologous peripheral blood stem cells. Cell Tissue Bank. 2018; 19 (4): 831–2. https://doi.org/10.1007/s10561-018-9718-x.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Hequet O., Dumontet C., El Jaafari-Corbin A., et al. Epileptic seizures after autologous peripheral blood progenitor infusion in a patient treated with high-dose chemotherapy for myeloma. Bone Marrow Transplant. 2002; 29 (6): 544. https://doi.org/10.1038/sj.bmt.1703383.</mixed-citation><mixed-citation xml:lang="en">Hequet O., Dumontet C., El Jaafari-Corbin A., et al. Epileptic seizures after autologous peripheral blood progenitor infusion in a patient treated with high-dose chemotherapy for myeloma. Bone Marrow Transplant. 2002; 29 (6): 544. https://doi.org/10.1038/sj.bmt.1703383.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Inaba H., Khan R.B., Laningham F.H., et al. Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol. 2008; 19 (1): 178–84. https://doi.org/10.1093/annonc/mdm466.</mixed-citation><mixed-citation xml:lang="en">Inaba H., Khan R.B., Laningham F.H., et al. Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol. 2008; 19 (1): 178–84. https://doi.org/10.1093/annonc/mdm466.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Rao R.D., Swanson J.W., Dejesus R.S., et al. Methotrexate induced seizures associated with acute reversible magnetic resonance imaging (MRI) changes in a patient with acute lymphoblastic leukemia. Leuk Lymphoma. 2002; 43 (6): 1333–6. https://doi.org/10.1080/10428190290026402.</mixed-citation><mixed-citation xml:lang="en">Rao R.D., Swanson J.W., Dejesus R.S., et al. Methotrexate induced seizures associated with acute reversible magnetic resonance imaging (MRI) changes in a patient with acute lymphoblastic leukemia. Leuk Lymphoma. 2002; 43 (6): 1333–6. https://doi.org/10.1080/10428190290026402.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Abraham P., Longardner K., Chen P., et al. Case 279: central-variant posterior reversible encephalopathy syndrome. Radiology. 2020; 296 (1): 239–43. https://doi.org/10.1148/radiol.2020181547.</mixed-citation><mixed-citation xml:lang="en">Abraham P., Longardner K., Chen P., et al. Case 279: central-variant posterior reversible encephalopathy syndrome. Radiology. 2020; 296 (1): 239–43. https://doi.org/10.1148/radiol.2020181547.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Teimouri A., Ahmadi S.R., Anavri Ardakani S., Foroughian M. Cyclosporine-A-based immunosuppressive therapy-induced neurotoxicity: a case report. Open Access Emerg Med. 2020; 2000 (12): 93–7. https://doi.org/10.2147/OAEM.S241501.</mixed-citation><mixed-citation xml:lang="en">Teimouri A., Ahmadi S.R., Anavri Ardakani S., Foroughian M. Cyclosporine-A-based immunosuppressive therapy-induced neurotoxicity: a case report. Open Access Emerg Med. 2020; 2000 (12): 93–7. https://doi.org/10.2147/OAEM.S241501.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">He W., Chen J., Wang Y.Y., et. al. Sirolimus improves seizure control in pediatric patients with tuberous sclerosis: a prospective cohort study. Seizure. 2020; 79: 20–6. https://doi.org/10.1016/j.seizure.2020.03.018.</mixed-citation><mixed-citation xml:lang="en">He W., Chen J., Wang Y.Y., et. al. Sirolimus improves seizure control in pediatric patients with tuberous sclerosis: a prospective cohort study. Seizure. 2020; 79: 20–6. https://doi.org/10.1016/j.seizure.2020.03.018.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Xie M., Rao W., Sun L.Y., et al. Tacrolimus-related seizure after pediatric liver transplantation – a single-center experience. Pediatr Transplant. 2014; 18 (1): 58–63. https://doi.org/10.1111/petr.12198.</mixed-citation><mixed-citation xml:lang="en">Xie M., Rao W., Sun L.Y., et al. Tacrolimus-related seizure after pediatric liver transplantation – a single-center experience. Pediatr Transplant. 2014; 18 (1): 58–63. https://doi.org/10.1111/petr.12198.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Sevmis S., Karakayali H., Emiroglu R., et al. Tacrolimus-related seizure in the early postoperative period after liver transplantation. Transplant Proc. 2007; 39 (4): 1211–3. https://doi.org/10.1016/j.transproceed.2007.02.049.</mixed-citation><mixed-citation xml:lang="en">Sevmis S., Karakayali H., Emiroglu R., et al. Tacrolimus-related seizure in the early postoperative period after liver transplantation. Transplant Proc. 2007; 39 (4): 1211–3. https://doi.org/10.1016/j.transproceed.2007.02.049.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Vesole A.S., Nagahama Y., Granner M.A., et al. Drug-resistant epilepsy development following stem cell transplant and cyclosporine neurotoxicity induced seizures: case report in an adult and analysis of reported cases in the literature. Epilepsy Behav Case Rep. 2018; 10: 8–13. https://doi.org/10.1016/j.ebcr.2018.01.002.</mixed-citation><mixed-citation xml:lang="en">Vesole A.S., Nagahama Y., Granner M.A., et al. Drug-resistant epilepsy development following stem cell transplant and cyclosporine neurotoxicity induced seizures: case report in an adult and analysis of reported cases in the literature. Epilepsy Behav Case Rep. 2018; 10: 8–13. https://doi.org/10.1016/j.ebcr.2018.01.002.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Kadish N.E., Riedel C., Stephani U., Wiegand G. Developmental outcomes in children/adolescents and one adult with tuberous sclerosis complex (TSC) and refractory epilepsy treated with everolimus. Epilepsy Behav. 2020; 111: 107182. https://doi.org/10.1016/j.yebeh.2020.107182.</mixed-citation><mixed-citation xml:lang="en">Kadish N.E., Riedel C., Stephani U., Wiegand G. Developmental outcomes in children/adolescents and one adult with tuberous sclerosis complex (TSC) and refractory epilepsy treated with everolimus. Epilepsy Behav. 2020; 111: 107182. https://doi.org/10.1016/j.yebeh.2020.107182.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Hung J.J., Huang J.L. Etanercept therapy in children with juvenile rheumatoid arthritis. J Microbiol Immunol Infect. 2005; 38 (6): 444–6.</mixed-citation><mixed-citation xml:lang="en">Hung J.J., Huang J.L. Etanercept therapy in children with juvenile rheumatoid arthritis. J Microbiol Immunol Infect. 2005; 38 (6): 444–6.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Cannon J.P., Lee T.A., Clark N.M., et al. The risk of seizures among the carbapenems: a meta-analysis. J Antimicrob Chemother. 2014; 69 (8): 2043–55. https://doi.org/10.1093/jac/dku111.</mixed-citation><mixed-citation xml:lang="en">Cannon J.P., Lee T.A., Clark N.M., et al. The risk of seizures among the carbapenems: a meta-analysis. J Antimicrob Chemother. 2014; 69 (8): 2043–55. https://doi.org/10.1093/jac/dku111.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Conley T.E., Mohiuddin A., Naz N. Severe co-trimoxazole-induced hypoglycaemia in a patient with microscopic polyangiitis. BMJ Case Rep. 2017; 2017: bcr2016218976. https://doi.org/10.1136/bcr-2016-218976.</mixed-citation><mixed-citation xml:lang="en">Conley T.E., Mohiuddin A., Naz N. Severe co-trimoxazole-induced hypoglycaemia in a patient with microscopic polyangiitis. BMJ Case Rep. 2017; 2017: bcr2016218976. https://doi.org/10.1136/bcr-2016-218976.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Balkan I.I., Delil S., Karabacak E.R., et al. Linezolid-induced complex partial seizure in a patient without epilepsy. Int J Infect Dis. 2015; 35: 120. https://doi.org/10.1016/j.ijid.2015.05.007.</mixed-citation><mixed-citation xml:lang="en">Balkan I.I., Delil S., Karabacak E.R., et al. Linezolid-induced complex partial seizure in a patient without epilepsy. Int J Infect Dis. 2015; 35: 120. https://doi.org/10.1016/j.ijid.2015.05.007.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Lin C.S., Cheng C.J., Chou C.H., Lin S.H. Piperacillin/tazobactaminduced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis. Am J Med Sci. 2007; 333 (3): 181–4. https://doi.org/10.1097/MAJ.0b013e31803195e7.</mixed-citation><mixed-citation xml:lang="en">Lin C.S., Cheng C.J., Chou C.H., Lin S.H. Piperacillin/tazobactaminduced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis. Am J Med Sci. 2007; 333 (3): 181–4. https://doi.org/10.1097/MAJ.0b013e31803195e7.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Chow K.M., Szeto C.C., Hui A.C., et al. Retrospective review of neurotoxicity induced by cefepime and ceftazidime. Pharmacotherapy. 2003; 23 (3): 369–73. https://doi.org/10.1592/phco.23.3.369.32100.</mixed-citation><mixed-citation xml:lang="en">Chow K.M., Szeto C.C., Hui A.C., et al. Retrospective review of neurotoxicity induced by cefepime and ceftazidime. Pharmacotherapy. 2003; 23 (3): 369–73. https://doi.org/10.1592/phco.23.3.369.32100.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Grill M.F., Maganti R. Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring. Ann Pharmacother. 2008; 42 (12): 1843–50. https://doi.org/10.1345/aph.1L307.</mixed-citation><mixed-citation xml:lang="en">Grill M.F., Maganti R. Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring. Ann Pharmacother. 2008; 42 (12): 1843–50. https://doi.org/10.1345/aph.1L307.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Agbaht K., Bitik B., Piskinpasa S., et al. Ciprofloxacin-associated seizures in a patient with underlying thyrotoxicosis: case report and literature review. Int J Clinl Pharmacol Ther. 2009; 47 (5): 303–10. https://doi.org/10.5414/cpp47303.</mixed-citation><mixed-citation xml:lang="en">Agbaht K., Bitik B., Piskinpasa S., et al. Ciprofloxacin-associated seizures in a patient with underlying thyrotoxicosis: case report and literature review. Int J Clinl Pharmacol Ther. 2009; 47 (5): 303–10. https://doi.org/10.5414/cpp47303.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Barton T.L., Roush M.K., Dever L.L. Seizures associated with ganciclovir therapy. Pharmacotherapy. 1992; 12 (5): 413–5.</mixed-citation><mixed-citation xml:lang="en">Barton T.L., Roush M.K., Dever L.L. Seizures associated with ganciclovir therapy. Pharmacotherapy. 1992; 12 (5): 413–5.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Foroughinia F., Baniasadi S., Seifi S., Fahimi F. Vincristine-induced seizure potentiated by itraconazole following RCHOP chemotherapy for diffuse large B-cell lymphoma. Curr Drug Saf. 2012; 7 (5): 372–4. https://doi.org/10.2174/157488612805076633.</mixed-citation><mixed-citation xml:lang="en">Foroughinia F., Baniasadi S., Seifi S., Fahimi F. Vincristine-induced seizure potentiated by itraconazole following RCHOP chemotherapy for diffuse large B-cell lymphoma. Curr Drug Saf. 2012; 7 (5): 372–4. https://doi.org/10.2174/157488612805076633.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Hamdy D.A., El-Geed H., El-Salem S., Zaidan M. Posaconazolevincristine coadministration triggers seizure in a young female adult: a case report. Case Rep Hematol. 2012; 2012: 343742. https://doi.org/10.1155/2012/343742.</mixed-citation><mixed-citation xml:lang="en">Hamdy D.A., El-Geed H., El-Salem S., Zaidan M. Posaconazolevincristine coadministration triggers seizure in a young female adult: a case report. Case Rep Hematol. 2012; 2012: 343742. https://doi.org/10.1155/2012/343742.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Beghi E., Carpio A., Forsgren L., et al. Recommendation for a definition of acute symptomatic seizure. Epilepsia. 2010; 51 (4): 671–5. https://doi.org/10.1111/j.1528-1167.2009.02285.x.</mixed-citation><mixed-citation xml:lang="en">Beghi E., Carpio A., Forsgren L., et al. Recommendation for a definition of acute symptomatic seizure. Epilepsia. 2010; 51 (4): 671–5. https://doi.org/10.1111/j.1528-1167.2009.02285.x.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Common Terminology Criteria for Adverse Events (CTCAE). URL: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (дата обращения 02.04.2021).</mixed-citation><mixed-citation xml:lang="en">Common Terminology Criteria for Adverse Events (CTCAE). URL: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (дата обращения 02.04.2021).</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Saner F., Gu Y., Minouchehr S., et al. Neurological complications after cadaveric and living donor liver transplantation. J Neurol. 2006; 253 (5): 612–7. https://doi.org/10.1007/s00415-006-0069-3.</mixed-citation><mixed-citation xml:lang="en">Saner F., Gu Y., Minouchehr S., et al. Neurological complications after cadaveric and living donor liver transplantation. J Neurol. 2006; 253 (5): 612–7. https://doi.org/10.1007/s00415-006-0069-3.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Forgacs B., Merhav H.J., Lappin J., Mieles L. Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation. Transplant Proc. 2005; 37 (4): 1912–4. https://doi.org/10.1016/j.transproceed.2005.02.101.</mixed-citation><mixed-citation xml:lang="en">Forgacs B., Merhav H.J., Lappin J., Mieles L. Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation. Transplant Proc. 2005; 37 (4): 1912–4. https://doi.org/10.1016/j.transproceed.2005.02.101.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Shuto H., Kataoka Y., Fujisaki K., et al. Inhibition of GABA system involved in cyclosporine-induced convulsions. Life Sci. 1999; 65 (9): 879–87. https://doi.org/10.1016/s0024-3205(99)00318-5.</mixed-citation><mixed-citation xml:lang="en">Shuto H., Kataoka Y., Fujisaki K., et al. Inhibition of GABA system involved in cyclosporine-induced convulsions. Life Sci. 1999; 65 (9): 879–87. https://doi.org/10.1016/s0024-3205(99)00318-5.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Klawitter J., Gottschalk S., Hainz C., et al. Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism. Chem Res Toxicol. 2010; 23 (3): 608–19. https://doi.org/10.1021/tx900351q.</mixed-citation><mixed-citation xml:lang="en">Klawitter J., Gottschalk S., Hainz C., et al. Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism. Chem Res Toxicol. 2010; 23 (3): 608–19. https://doi.org/10.1021/tx900351q.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Katsarou A.M., Moshé S.L., Galanopoulou A.S. Interneuronopathies and their role in early life epilepsies and neurodevelopmental disorders. Epilepsia Open. 2017; 2 (3): 284–306. https://doi.org/10.1021/tx900351q10.1002/epi4.12062.</mixed-citation><mixed-citation xml:lang="en">Katsarou A.M., Moshé S.L., Galanopoulou A.S. Interneuronopathies and their role in early life epilepsies and neurodevelopmental disorders. Epilepsia Open. 2017; 2 (3): 284–306. https://doi.org/10.1021/tx900351q10.1002/epi4.12062.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Wong M., Yamada K.A. Cyclosporine induces epileptiform activity in an in vitro seizure model. Epilepsia. 2000; 41 (3): 271–6. https://doi.org/10.1111/j.1528-1157.2000.tb00155.x.</mixed-citation><mixed-citation xml:lang="en">Wong M., Yamada K.A. Cyclosporine induces epileptiform activity in an in vitro seizure model. Epilepsia. 2000; 41 (3): 271–6. https://doi.org/10.1111/j.1528-1157.2000.tb00155.x.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y., Wang H., Han D., et al. Acute symptomatic seizure due to tacrolimus-related encephalopathy after liver transplantation: two case reports. J Int Med Res. 2019; 47 (12): 6397–403. https://doi.org/10.1177/0300060519883750.</mixed-citation><mixed-citation xml:lang="en">Li Y., Wang H., Han D., et al. Acute symptomatic seizure due to tacrolimus-related encephalopathy after liver transplantation: two case reports. J Int Med Res. 2019; 47 (12): 6397–403. https://doi.org/10.1177/0300060519883750.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Savolainen H., Tenhunen R. Inhibition of heme synthase in brain and liver by low-level peroral sulfite exposure. Res Commun Chem Pathol Pharmacol. 1982; 36 (3): 511–4.</mixed-citation><mixed-citation xml:lang="en">Savolainen H., Tenhunen R. Inhibition of heme synthase in brain and liver by low-level peroral sulfite exposure. Res Commun Chem Pathol Pharmacol. 1982; 36 (3): 511–4.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Chen-Plotkin A.S., Vossel K.A., Samuels M.A., Chen M.H. Encephalopathy, stroke, and myocardial infarction with DMSO use in stem cell transplantation. Neurology. 2007; 68 (11): 859–61. https://doi.org/10.1212/01.wnl.0000256716.04218.5b.</mixed-citation><mixed-citation xml:lang="en">Chen-Plotkin A.S., Vossel K.A., Samuels M.A., Chen M.H. Encephalopathy, stroke, and myocardial infarction with DMSO use in stem cell transplantation. Neurology. 2007; 68 (11): 859–61. https://doi.org/10.1212/01.wnl.0000256716.04218.5b.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Ruiz-Delgado G.J., Mancías-Guerra C., Tamez-Gómez E.L., et al. Dimethyl sulfoxide-induced toxicity in cord blood stem cell transplantation: report of three cases and review of the literature. Acta Haematol. 2009; 122 (1): 1–5. https://doi.org/10.1159/000227267.</mixed-citation><mixed-citation xml:lang="en">Ruiz-Delgado G.J., Mancías-Guerra C., Tamez-Gómez E.L., et al. Dimethyl sulfoxide-induced toxicity in cord blood stem cell transplantation: report of three cases and review of the literature. Acta Haematol. 2009; 122 (1): 1–5. https://doi.org/10.1159/000227267.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Pillinger K.E., Bouchard J., Withers S.T., et al. Inpatient Antibiotic Stewardship Interventions in the adult oncology and hematopoietic stem cell transplant population: a review of the literature. Ann Pharmacother. 2020; 54 (6): 594–10. https://doi.org/10.1177/1060028019890886.</mixed-citation><mixed-citation xml:lang="en">Pillinger K.E., Bouchard J., Withers S.T., et al. Inpatient Antibiotic Stewardship Interventions in the adult oncology and hematopoietic stem cell transplant population: a review of the literature. Ann Pharmacother. 2020; 54 (6): 594–10. https://doi.org/10.1177/1060028019890886.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Rival M., Chetioui A., Tailland M., Renard D. Linezolid-induced status epilepticus. Acta Neurol Belg. 2020; 120 (5): 1231–2. https://doi.org/10.1007/s13760-020-01333-2.</mixed-citation><mixed-citation xml:lang="en">Rival M., Chetioui A., Tailland M., Renard D. Linezolid-induced status epilepticus. Acta Neurol Belg. 2020; 120 (5): 1231–2. https://doi.org/10.1007/s13760-020-01333-2.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Bora I., Demir A.B., Uzun P. Nonconvulsive status epilepticus cases arising in connection with cephalosporins. Epilepsy Behav Case Rep. 2016; 6: 23–7. https://doi.org/10.1016/j.ebcr.2016.04.005.</mixed-citation><mixed-citation xml:lang="en">Bora I., Demir A.B., Uzun P. Nonconvulsive status epilepticus cases arising in connection with cephalosporins. Epilepsy Behav Case Rep. 2016; 6: 23–7. https://doi.org/10.1016/j.ebcr.2016.04.005.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Meyer M.A. Myoclonic jerks secondary to piperacillin and nafcillin. Neurol Int. 2014; 6 (2): 5349. https://doi.org/10.4081/ni.2014.5349.</mixed-citation><mixed-citation xml:lang="en">Meyer M.A. Myoclonic jerks secondary to piperacillin and nafcillin. Neurol Int. 2014; 6 (2): 5349. https://doi.org/10.4081/ni.2014.5349.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Jang J.H., Song K.S., Bang J.S., et al. What should be considered to cause the early post-craniotomy seizure: antibiotics (cefazolin) irrigation. J Korean Neurosurg Soc. 2015; 58 (5): 462–6. https://doi.org/10.3340/jkns.2015.58.5.462.</mixed-citation><mixed-citation xml:lang="en">Jang J.H., Song K.S., Bang J.S., et al. What should be considered to cause the early post-craniotomy seizure: antibiotics (cefazolin) irrigation. J Korean Neurosurg Soc. 2015; 58 (5): 462–6. https://doi.org/10.3340/jkns.2015.58.5.462.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">McCune J.S., Wang T., Bo-Subait K., et al. Association of antiepileptic medications with outcomes after allogeneic hematopoietic cell transplantation with busulfan/cyclophosphamide conditioning. Biol Blood Marrow Transplant. 2019; 25 (7): 1424–31. https://doi.org/10.1016/j.bbmt.2019.03.001.</mixed-citation><mixed-citation xml:lang="en">McCune J.S., Wang T., Bo-Subait K., et al. Association of antiepileptic medications with outcomes after allogeneic hematopoietic cell transplantation with busulfan/cyclophosphamide conditioning. Biol Blood Marrow Transplant. 2019; 25 (7): 1424–31. https://doi.org/10.1016/j.bbmt.2019.03.001.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Nardone R., Brigo F., Trinka E. Acute symptomatic seizures caused by electrolyte disturbances. J Clin Neurol. 2016; 12 (1): 21–33. https://doi.org/10.3988/jcn.2016.12.1.21.</mixed-citation><mixed-citation xml:lang="en">Nardone R., Brigo F., Trinka E. Acute symptomatic seizures caused by electrolyte disturbances. J Clin Neurol. 2016; 12 (1): 21–33. https://doi.org/10.3988/jcn.2016.12.1.21.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Schwartzkroin P.A., Baraban S.C., Hochman D.W. Osmolarity, ionic flux, and changes in brain excitability. Epilepsy Res. 1998; 32 (1-2): 275–85. https://doi.org/10.1016/s0920-1211(98)00058-8.</mixed-citation><mixed-citation xml:lang="en">Schwartzkroin P.A., Baraban S.C., Hochman D.W. Osmolarity, ionic flux, and changes in brain excitability. Epilepsy Res. 1998; 32 (1-2): 275–85. https://doi.org/10.1016/s0920-1211(98)00058-8.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Filippatos T.D., Milionis H.J., Elisaf M.S. Alterations in electrolyte equilibrium in patients with acute leukemia. Eur J Haematol. 2005; 75 (6): 449–60. https://doi.org/10.1111/j.1600-0609.2005.00547.x.</mixed-citation><mixed-citation xml:lang="en">Filippatos T.D., Milionis H.J., Elisaf M.S. Alterations in electrolyte equilibrium in patients with acute leukemia. Eur J Haematol. 2005; 75 (6): 449–60. https://doi.org/10.1111/j.1600-0609.2005.00547.x.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Anandan A., Kolk M., Ferrari N., et al. Serum electrolyte dynamics in multiple myeloma patients undergoing autologous haematopoietic stem cell transplantation. Nephrology (Carlton). 2020; 25 (6): 450–6. https://doi.org/10.1111/nep.13712.</mixed-citation><mixed-citation xml:lang="en">Anandan A., Kolk M., Ferrari N., et al. Serum electrolyte dynamics in multiple myeloma patients undergoing autologous haematopoietic stem cell transplantation. Nephrology (Carlton). 2020; 25 (6): 450–6. https://doi.org/10.1111/nep.13712.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Milionis H.J., Bourantas C.L., Siamopoulos K.C., et al. Acid-base and electrolyte abnormalities in patients with acute leukemia. Am J Hematol. 1999; 62 (4): 201–7. https://doi.org/10.1002/(sici)1096-8652(199912)62:4&lt;201::aid-ajh1&gt;3.0.co;2-1.</mixed-citation><mixed-citation xml:lang="en">Milionis H.J., Bourantas C.L., Siamopoulos K.C., et al. Acid-base and electrolyte abnormalities in patients with acute leukemia. Am J Hematol. 1999; 62 (4): 201–7. https://doi.org/10.1002/(sici)1096-8652(199912)62:4&lt;201::aid-ajh1&gt;3.0.co;2-1.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Philibert D., Desmeules S., Filion A., et al. Incidence and severity of early electrolyte abnormalities following autologous haematopoietic stem cell transplantation. Nephrol Dial Transplant. 2008; 23 (1): 359–63. https://doi.org/10.1093/ndt/gfm571.</mixed-citation><mixed-citation xml:lang="en">Philibert D., Desmeules S., Filion A., et al. Incidence and severity of early electrolyte abnormalities following autologous haematopoietic stem cell transplantation. Nephrol Dial Transplant. 2008; 23 (1): 359–63. https://doi.org/10.1093/ndt/gfm571.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Van Amelsvoort T., Bakshi R., Devaux C.B., Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia. 1994; 35 (1): 181–8. https://doi.org/10.1111/j.1528-1157.1994.tb02930.x.</mixed-citation><mixed-citation xml:lang="en">Van Amelsvoort T., Bakshi R., Devaux C.B., Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia. 1994; 35 (1): 181–8. https://doi.org/10.1111/j.1528-1157.1994.tb02930.x.</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">de Leeuw D.C., Kooter A.J. Transient seizure-induced sodium increase camouflaging a symptomatic hyponatremia. BMJ Case Rep. 2020; 13 (1): e229328. https://doi.org/10.1136/bcr-2019-229328.</mixed-citation><mixed-citation xml:lang="en">de Leeuw D.C., Kooter A.J. Transient seizure-induced sodium increase camouflaging a symptomatic hyponatremia. BMJ Case Rep. 2020; 13 (1): e229328. https://doi.org/10.1136/bcr-2019-229328.</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Pilato F., Distefano M., Calandrelli R. Posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome: clinical and radiological considerations. Front Neurol. 2020; 11: 34. https://doi.org/10.3389/fneur.2020.00034.</mixed-citation><mixed-citation xml:lang="en">Pilato F., Distefano M., Calandrelli R. Posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome: clinical and radiological considerations. Front Neurol. 2020; 11: 34. https://doi.org/10.3389/fneur.2020.00034.</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Q., Zhao X., Fu H.X., et al. Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplant. 2020; 55 (10): 2035–42. https://doi.org/10.1038/s41409-020-0894-5.</mixed-citation><mixed-citation xml:lang="en">Chen Q., Zhao X., Fu H.X., et al. Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplant. 2020; 55 (10): 2035–42. https://doi.org/10.1038/s41409-020-0894-5.</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Datar S., Singh T., Rabinstein A.A., et al. Long-term risk of seizures and epilepsy in patients with posterior reversible encephalopathy syndrome. Epilepsia. 2015; 56 (4): 564–8. https://doi.org/10.1111/epi.12933.</mixed-citation><mixed-citation xml:lang="en">Datar S., Singh T., Rabinstein A.A., et al. Long-term risk of seizures and epilepsy in patients with posterior reversible encephalopathy syndrome. Epilepsia. 2015; 56 (4): 564–8. https://doi.org/10.1111/epi.12933.</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Hammerstrom A.E., Howell J., Gulbis A., et al. Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. Am J Hematol. 2013; 88 (4): 301–5. https://doi.org/10.1002/ajh.23402.</mixed-citation><mixed-citation xml:lang="en">Hammerstrom A.E., Howell J., Gulbis A., et al. Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. Am J Hematol. 2013; 88 (4): 301–5. https://doi.org/10.1002/ajh.23402.</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Gaziev J., Marziali S., Paciaroni K., et al. Posterior reversible encephalopathy syndrome after hematopoietic cell transplantation in children with hemoglobinopathies. Biol Blood Marrow Transpl. 2017; 23 (9): 1531–40. https://doi.org/10.1016/j.bbmt.2017.05.033.</mixed-citation><mixed-citation xml:lang="en">Gaziev J., Marziali S., Paciaroni K., et al. Posterior reversible encephalopathy syndrome after hematopoietic cell transplantation in children with hemoglobinopathies. Biol Blood Marrow Transpl. 2017; 23 (9): 1531–40. https://doi.org/10.1016/j.bbmt.2017.05.033.</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">April D., Lall N., Steven A. Stroke-like migraine attacks after radiation therapy syndrome. Ochsner J. 2020; 20 (1): 6–9. https://doi.org/10.31486/toj.19.0090.</mixed-citation><mixed-citation xml:lang="en">April D., Lall N., Steven A. Stroke-like migraine attacks after radiation therapy syndrome. Ochsner J. 2020; 20 (1): 6–9. https://doi.org/10.31486/toj.19.0090.</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Kerklaan J.P., Lycklama á Nijeholt G.J., Wiggenraad R.G., et al. SMART syndrome: a late reversible complication after radiation therapy for brain tumours. J Neurol. 2011; 258 (6): 1098–104. https://doi.org/10.1007/s00415-010-5892-x.</mixed-citation><mixed-citation xml:lang="en">Kerklaan J.P., Lycklama á Nijeholt G.J., Wiggenraad R.G., et al. SMART syndrome: a late reversible complication after radiation therapy for brain tumours. J Neurol. 2011; 258 (6): 1098–104. https://doi.org/10.1007/s00415-010-5892-x.</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Farid K., Meissner W.G., Samier-Foubert A., et al. Normal cerebrovascular reactivity in stroke-like migraine attacks after radiation therapy syndrome. Clin Nucl Med. 2010; 35 (8): 583–5. https://doi.org/10.1097/RLU.0b013e3181e4db6f.</mixed-citation><mixed-citation xml:lang="en">Farid K., Meissner W.G., Samier-Foubert A., et al. Normal cerebrovascular reactivity in stroke-like migraine attacks after radiation therapy syndrome. Clin Nucl Med. 2010; 35 (8): 583–5. https://doi.org/10.1097/RLU.0b013e3181e4db6f.</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Suarez Montero J.C., Caballero Gonzalez A.C., Martín Aguilar L., Mancebo Cortés J. Immune effector cell-associated neurotoxicity syndrome: a therapeutic approach in the critically ill. Med Intensiva. 2020: S0210-5691(20)30244-8. https://doi.org/10.1016/j.medin.2020.06.014.</mixed-citation><mixed-citation xml:lang="en">Suarez Montero J.C., Caballero Gonzalez A.C., Martín Aguilar L., Mancebo Cortés J. Immune effector cell-associated neurotoxicity syndrome: a therapeutic approach in the critically ill. Med Intensiva. 2020: S0210-5691(20)30244-8. https://doi.org/10.1016/j.medin.2020.06.014.</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Perrin P., Collongues N., Baloglu S., et al. Cytokine release syndromeassociated encephalopathy in patients with COVID-19. Eur J Neurol. 2021; 28 (1): 248–58. https://doi.org/10.1111/ene.14491.</mixed-citation><mixed-citation xml:lang="en">Perrin P., Collongues N., Baloglu S., et al. Cytokine release syndromeassociated encephalopathy in patients with COVID-19. Eur J Neurol. 2021; 28 (1): 248–58. https://doi.org/10.1111/ene.14491.</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Borrega J.G., Gödel P., Rüger M.A., et al. In the eye of the storm: immune-mediated toxicities associated with CAR-T cell therapy. Hemasphere. 2019; 3 (2): e191. https://doi.org/10.1097/HS9.0000000000000191.</mixed-citation><mixed-citation xml:lang="en">Borrega J.G., Gödel P., Rüger M.A., et al. In the eye of the storm: immune-mediated toxicities associated with CAR-T cell therapy. Hemasphere. 2019; 3 (2): e191. https://doi.org/10.1097/HS9.0000000000000191.</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Gust J., Finney O.C., Li D., et al. Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Ann Neurol. 2019; 86 (1): 42–54. https://doi.org/10.1002/ana.25502.</mixed-citation><mixed-citation xml:lang="en">Gust J., Finney O.C., Li D., et al. Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Ann Neurol. 2019; 86 (1): 42–54. https://doi.org/10.1002/ana.25502.</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Gust J., Hay K.A., Hanafi L.A., et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017; 7 (12): 1404–9. https://doi.org/10.1158/2159-8290.CD-17-0698.</mixed-citation><mixed-citation xml:lang="en">Gust J., Hay K.A., Hanafi L.A., et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017; 7 (12): 1404–9. https://doi.org/10.1158/2159-8290.CD-17-0698.</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Zheng W. Neurotoxicology of the brain barrier system: new implications. J Toxicol Clin Toxicol. 2001; 39 (7): 711–9. https://doi.org/10.1081/clt-100108512.</mixed-citation><mixed-citation xml:lang="en">Zheng W. Neurotoxicology of the brain barrier system: new implications. J Toxicol Clin Toxicol. 2001; 39 (7): 711–9. https://doi.org/10.1081/clt-100108512.</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Martell R.W., Sher C., Jacobs P., Monteagudo F. High-dose busulfan and myoclonic epilepsy. Ann Intern Med. 1987; 106 (1): 173. https://doi.org/10.7326/0003-4819-106-1-173_1.</mixed-citation><mixed-citation xml:lang="en">Martell R.W., Sher C., Jacobs P., Monteagudo F. High-dose busulfan and myoclonic epilepsy. Ann Intern Med. 1987; 106 (1): 173. https://doi.org/10.7326/0003-4819-106-1-173_1.</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Janssen S., Bloem B.R., van de Warrenburg B.P. The clinical heterogeneity of drug-induced myoclonus: an illustrated review. J Neurol. 2017; 264 (8): 1559–66. https://doi.org/10.1007/s00415-016-8357-z.</mixed-citation><mixed-citation xml:lang="en">Janssen S., Bloem B.R., van de Warrenburg B.P. The clinical heterogeneity of drug-induced myoclonus: an illustrated review. J Neurol. 2017; 264 (8): 1559–66. https://doi.org/10.1007/s00415-016-8357-z.</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Dowling M.R., Li S., Dey B.R., et al. Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact. Bone Marrow Transplant. 2018; 53 (2): 199–206. https://doi.org/10.1038/bmt.2017.239.</mixed-citation><mixed-citation xml:lang="en">Dowling M.R., Li S., Dey B.R., et al. Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact. Bone Marrow Transplant. 2018; 53 (2): 199–206. https://doi.org/10.1038/bmt.2017.239.</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">Hamidieh A.A., Hamedani R., Hadjibabaie M., et al. Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study. Pediatr Hematol Oncol. 2010; 27 (7): 529–33. https://doi.org/10.3109/08880018.2010.496895.</mixed-citation><mixed-citation xml:lang="en">Hamidieh A.A., Hamedani R., Hadjibabaie M., et al. Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study. Pediatr Hematol Oncol. 2010; 27 (7): 529–33. https://doi.org/10.3109/08880018.2010.496895.</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">Ruiz-Argüelles G.J., Gomez-Almaguer D., Steensma D.P. Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting. Am J Hematol. 2012; 87 (9): 941. https://doi.org/10.1002/ajh.23270.</mixed-citation><mixed-citation xml:lang="en">Ruiz-Argüelles G.J., Gomez-Almaguer D., Steensma D.P. Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting. Am J Hematol. 2012; 87 (9): 941. https://doi.org/10.1002/ajh.23270.</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Diaz-Carrasco M.S., Olmos R., Blanquer M., et al. Clonazepam for seizure prophylaxis in adult patients treated with high dose busulfan. Int J Clin Pharm. 2013; 35 (3): 339–43. https://doi.org/10.1007/s11096-013-9768-x.</mixed-citation><mixed-citation xml:lang="en">Diaz-Carrasco M.S., Olmos R., Blanquer M., et al. Clonazepam for seizure prophylaxis in adult patients treated with high dose busulfan. Int J Clin Pharm. 2013; 35 (3): 339–43. https://doi.org/10.1007/s11096-013-9768-x.</mixed-citation></citation-alternatives></ref><ref id="cit93"><label>93</label><citation-alternatives><mixed-citation xml:lang="ru">Chan K.W., Mullen C.A., Worth L.L., et al. Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone Marrow Transplant. 2002; 29 (12): 963–5. https://doi.org/10.1038/sj.bmt.1703593.</mixed-citation><mixed-citation xml:lang="en">Chan K.W., Mullen C.A., Worth L.L., et al. Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone Marrow Transplant. 2002; 29 (12): 963–5. https://doi.org/10.1038/sj.bmt.1703593.</mixed-citation></citation-alternatives></ref><ref id="cit94"><label>94</label><citation-alternatives><mixed-citation xml:lang="ru">Hassan M., Oberg G., Björkholm M., et al. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol. 1993; 33 (3): 181–6. https://doi.org/10.1007/BF00686213.</mixed-citation><mixed-citation xml:lang="en">Hassan M., Oberg G., Björkholm M., et al. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol. 1993; 33 (3): 181–6. https://doi.org/10.1007/BF00686213.</mixed-citation></citation-alternatives></ref><ref id="cit95"><label>95</label><citation-alternatives><mixed-citation xml:lang="ru">Carreras E., Cahn J.Y., Puozzo C., et al. Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data. Anticancer Res. 2010; 30 (7): 2977–84.</mixed-citation><mixed-citation xml:lang="en">Carreras E., Cahn J.Y., Puozzo C., et al. Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data. Anticancer Res. 2010; 30 (7): 2977–84.</mixed-citation></citation-alternatives></ref><ref id="cit96"><label>96</label><citation-alternatives><mixed-citation xml:lang="ru">Chaguaceda C., Aguilera-Jiménez V., Gutierrez G., et al. Oral levetiracetam for prevention of busulfan-induced seizures in adult hematopoietic cell transplant. Int J Clin Pharm. 2020; 42 (2): 351–4. https://doi.org/10.1007/s11096-020-00977-7.</mixed-citation><mixed-citation xml:lang="en">Chaguaceda C., Aguilera-Jiménez V., Gutierrez G., et al. Oral levetiracetam for prevention of busulfan-induced seizures in adult hematopoietic cell transplant. Int J Clin Pharm. 2020; 42 (2): 351–4. https://doi.org/10.1007/s11096-020-00977-7.</mixed-citation></citation-alternatives></ref><ref id="cit97"><label>97</label><citation-alternatives><mixed-citation xml:lang="ru">Floeter A.E., Mccune J.S. Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients. J Oncol Pharm Pract. 2017; 23 (5). https://doi.org/10.1177/1078155216651128.</mixed-citation><mixed-citation xml:lang="en">Floeter A.E., Mccune J.S. Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients. J Oncol Pharm Pract. 2017; 23 (5). https://doi.org/10.1177/1078155216651128.</mixed-citation></citation-alternatives></ref><ref id="cit98"><label>98</label><citation-alternatives><mixed-citation xml:lang="ru">Eberly A.L., Anderson G.D., Bubalo J.S., McCune J.S. Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy. 2008; 28 (12): 1502–10. https://doi.org/10.1592/phco.28.12.1502.</mixed-citation><mixed-citation xml:lang="en">Eberly A.L., Anderson G.D., Bubalo J.S., McCune J.S. Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy. 2008; 28 (12): 1502–10. https://doi.org/10.1592/phco.28.12.1502.</mixed-citation></citation-alternatives></ref><ref id="cit99"><label>99</label><citation-alternatives><mixed-citation xml:lang="ru">Marcus R.E., Goldman J.M. Convulsions due to high-dose busulphan. Lancet. 1984; 2 (8417-8418): 1463. https://doi.org/10.1016/s0140-6736(84)91649-0.</mixed-citation><mixed-citation xml:lang="en">Marcus R.E., Goldman J.M. Convulsions due to high-dose busulphan. Lancet. 1984; 2 (8417-8418): 1463. https://doi.org/10.1016/s0140-6736(84)91649-0.</mixed-citation></citation-alternatives></ref><ref id="cit100"><label>100</label><citation-alternatives><mixed-citation xml:lang="ru">Vassal G., Deroussent A., Hartmann O., et al.. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res. 1990; 50 (19): 6203–7.</mixed-citation><mixed-citation xml:lang="en">Vassal G., Deroussent A., Hartmann O., et al.. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res. 1990; 50 (19): 6203–7.</mixed-citation></citation-alternatives></ref><ref id="cit101"><label>101</label><citation-alternatives><mixed-citation xml:lang="ru">Woodward S. Management of faecal incontinence in graft-versus-host disease. Br J Nurs. 2012; 21 (2): 84–8. https://doi.org/10.12968/bjon.2012.21.2.84.</mixed-citation><mixed-citation xml:lang="en">Woodward S. Management of faecal incontinence in graft-versus-host disease. Br J Nurs. 2012; 21 (2): 84–8. https://doi.org/10.12968/bjon.2012.21.2.84.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
